Novo Nordisk A/S (NYSE:NVO) Stock Holdings Lifted by Redhawk Wealth Advisors Inc.

Redhawk Wealth Advisors Inc. lifted its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 12.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,361 shares of the company’s stock after purchasing an additional 2,406 shares during the quarter. Redhawk Wealth Advisors Inc.’s holdings in Novo Nordisk A/S were worth $1,837,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of the business. Novare Capital Management LLC lifted its holdings in shares of Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after purchasing an additional 85 shares during the last quarter. Steel Grove Capital Advisors LLC increased its position in Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock worth $541,000 after buying an additional 86 shares during the period. Benjamin Edwards Inc. lifted its stake in Novo Nordisk A/S by 2.6% in the second quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock valued at $493,000 after buying an additional 87 shares during the last quarter. Rosenberg Matthew Hamilton boosted its stake in Novo Nordisk A/S by 2.5% during the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after purchasing an additional 94 shares during the period. Finally, Burns J W & Co. Inc. NY increased its stake in shares of Novo Nordisk A/S by 1.9% in the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock valued at $647,000 after purchasing an additional 100 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.2 %

Novo Nordisk A/S stock opened at $82.99 on Thursday. Novo Nordisk A/S has a 12 month low of $80.05 and a 12 month high of $148.15. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The stock has a market cap of $372.42 billion, a P/E ratio of 26.86, a P/E/G ratio of 0.92 and a beta of 0.45. The company’s fifty day simple moving average is $99.26 and its 200-day simple moving average is $118.18.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. Finally, StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.